Armata Pharmaceuticals Statistics
Share Statistics
Armata Pharmaceuticals has 36.18M shares outstanding. The number of shares has increased by 0.1% in one year.
| Shares Outstanding | 36.18M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.08% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 10.76M |
| Failed to Deliver (FTD) Shares | 685 |
| FTD / Avg. Volume | 9.02% |
Short Selling Information
The latest short interest is 4.54K, so 0.01% of the outstanding shares have been sold short.
| Short Interest | 4.54K |
| Short % of Shares Out | 0.01% |
| Short % of Float | 0.04% |
| Short Ratio (days to cover) | 0.86 |
Valuation Ratios
The PE ratio is -1.69 and the forward PE ratio is -1.75.
| PE Ratio | -1.69 |
| Forward PE | -1.75 |
| PS Ratio | 25.81 |
| Forward PS | 14.4 |
| PB Ratio | -3.65 |
| P/FCF Ratio | -2.1 |
| PEG Ratio | n/a |
Enterprise Valuation
Armata Pharmaceuticals Inc. has an Enterprise Value (EV) of 223.73M.
| EV / Earnings | -3.24 |
| EV / Sales | 49.4 |
| EV / EBITDA | -5.6 |
| EV / EBIT | -5.47 |
| EV / FCF | -4.03 |
Financial Position
The company has a current ratio of 1.16, with a Debt / Equity ratio of -2.86.
| Current Ratio | 1.16 |
| Quick Ratio | 1.16 |
| Debt / Equity | -2.86 |
| Total Debt / Capitalization | 153.69 |
| Cash Flow / Debt | -0.52 |
| Interest Coverage | -15.57 |
Financial Efficiency
Return on equity (ROE) is 2.15% and return on capital (ROIC) is -46.3%.
| Return on Equity (ROE) | 2.15% |
| Return on Assets (ROA) | -0.7% |
| Return on Capital (ROIC) | -46.3% |
| Revenue Per Employee | 68.62K |
| Profits Per Employee | -1.05M |
| Employee Count | 66 |
| Asset Turnover | 0.05 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -8.75% in the last 52 weeks. The beta is 0.81, so Armata Pharmaceuticals 's price volatility has been higher than the market average.
| Beta | 0.81 |
| 52-Week Price Change | -8.75% |
| 50-Day Moving Average | 2.31 |
| 200-Day Moving Average | 2.71 |
| Relative Strength Index (RSI) | 41.06 |
| Average Volume (20 Days) | 7.60K |
Income Statement
In the last 12 months, Armata Pharmaceuticals had revenue of $4.53M and earned -$69.05M in profits. Earnings per share was $-1.91.
| Revenue | 4.53M |
| Gross Profit | -29.24M |
| Operating Income | -40.89M |
| Net Income | -69.05M |
| EBITDA | -39.92M |
| EBIT | -40.89M |
| Earnings Per Share (EPS) | -1.91 |
Balance Sheet
The company has $13.52M in cash and $120.37M in debt, giving a net cash position of -$106.85M.
| Cash & Cash Equivalents | 13.52M |
| Total Debt | 120.37M |
| Net Cash | -106.85M |
| Retained Earnings | -308.82M |
| Total Assets | 98.24M |
| Working Capital | -95.81M |
Cash Flow
In the last 12 months, operating cash flow was -$47.42M and capital expenditures -$8.14M, giving a free cash flow of -$55.57M.
| Operating Cash Flow | -47.42M |
| Capital Expenditures | -8.14M |
| Free Cash Flow | -55.57M |
| FCF Per Share | -1.54 |
Margins
Gross margin is -645.64%, with operating and profit margins of -902.85% and -1.52K%.
| Gross Margin | -645.64% |
| Operating Margin | -902.85% |
| Pretax Margin | -1.52K% |
| Profit Margin | -1.52K% |
| EBITDA Margin | -881.39% |
| EBIT Margin | -902.85% |
| FCF Margin | -1.23K% |
Dividends & Yields
ARMP does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -87.21% |
| FCF Yield | -70.07% |
Analyst Forecast
The average price target for ARMP is $7, which is 219.6% higher than the current price. The consensus rating is "Buy".
| Price Target | $7 |
| Price Target Difference | 219.6% |
| Analyst Consensus | Buy |
| Analyst Count | 1 |
Stock Splits
The last stock split was on May 10, 2019. It was a backward split with a ratio of 1:14.
| Last Split Date | May 10, 2019 |
| Split Type | backward |
| Split Ratio | 1:14 |
Scores
| Altman Z-Score | -6.64 |
| Piotroski F-Score | 2 |